# FORTE (NCT02203643)

> Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02203643
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Mario Boccadoro
- Conditions: MULTIPLE MYELOMA (MM)
- Interventions: Carfilzomib; Cyclophosphamide; Lenalidomide; Dexamethasone
- Enrollment: 477
- Primary outcome: Efficacy in term of at least Very Good Partial Response (VGPR)

## Indexed commentary on FORTE so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=forte-nct02203643
